The National Institute of Allergy and Infectious Diseases has awarded a division of SRI International a potential five-year, $100 million contract to develop therapies for radiation exposure.
SRI Biosciences will carry out preclinical testing, good manufacturing practice development, stability studies, human clinical trials and formulation development work for NIAID under the multi-year contract, SRIÂ said Tuesday.
The division will also help the agency move drug candidates through the Food and Drug Administration’s approval process.
Polly Chang, senior director of molecular and genetic toxicology at SRI Biosciences, said it will leverage its experience in radiation biology research and drug development to support the project.
